Published Online:29 Nov 2018https://doi.org/10.2217/rme-2018-0120
Abstract
Human pluripotent stem cells (hPSCs) have the potential to transform medicine. However, hurdles remain to ensure safety for such cellular products. Science-based understanding of the requirements for source materials is required as are appropriate materials. Leaders in hPSC biology, clinical translation, biomanufacturing and regulatory issues were brought together to define requirements for source materials for the production of hPSC-derived therapies and to identify other key issues for the safety of cell therapy products. While the focus of this meeting was on hPSC-derived cell therapies, many of the issues are generic to all cell-based medicines. The intent of this report is to summarize the key issues discussed and record the consensus reached on each of these by the expert delegates.
Lay abstract
Cell therapies utilize cells provided with the consent of donors to generate preparations to restore tissue function in patients who have suffered injury or have some other disease. These preparations are diverse and often highly complex which means that that their manufacture requires great attention to assure they are safe and effective. This paper describes a conversation among experts in the field exploring these safety issues and what they mean for manufacturers.
Keywords:
Papers of special note have been highlighted as: • of interest; •• of considered interest
References
- 1 UK Regenerative Medicine Platform (UK RMP). www.ukrmp.org.uk/ • The UK Regenerative Medicine Platform supports scientific ‘hubs’ to provide new tools, protocols and resources with broad applicability across regenerative medicine.
- 2 . Quantification of biological variation in blood-based therapy: a summary of a meta-analysis to inform manufacturing in the clinic. Vox Sang. 109(4), 394–402 (2015).
- 3 Comparability: manufacturing, characterization and controls, report of a UK Regenerative Medicine Platform Pluripotent Stem Cell Platform Workshop, Trinity Hall, Cambridge, 14–15 September 2015. Regen Med. 11(5), 483–492 (2016). •• Discussion from a meeting of international academic and industrial experts, summarizing the key issues in assessment comparability of cell-therapy products.
- 4 Roslin. http://roslincells.com/latest-news/2013/9/11/cell-therapy-catapult-roslin-cells-to-create-clinical-grade.html
- 5 National Institute for Biological Standards and Control. www.nibsc.org/science_and_research/advanced_therapies/uk_stem_cell_bank/cell_lines/approved_by_the_bank.aspx
- 6 . Setting up a haplobank: issues and solutions. Curr. Stem Cell Rep. 1(2), 110–117 (2015).
- 7 Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell 13(4), 382–384 (2013).
- 8 European Commission Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. OJ L 311, 28.11.2001. 67 (2001). https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_cons2009/2001_83_cons2009_en.pdf
- 9 European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe. Symposium on Raw Materials for the Production of Cell based and Gene Therapy Products. EDQM Premises, Strasbourg, France, 3 April 2013. www.edqm.eu/medias/fichiers/session_2_user_manufacturer_and_academic_viewpoint.pdf
- 10 European Directorate for the Quality of Medicines & Healthcare (EDQM). European Pharmacopoeia (9th Ed.) DruckeriC.H. Beck, Nordlingen, Germany (2016). www.edqm.eu/en/european-pharmacopoeia-ph-eur-9th-edition
- 11 British Standards Institution (BSI). PAS 157: Evaluation of materials of biological origin used in the production of cell-based medicinal products (2015). http://shop.bsigroup.com/forms/PASs/PAS-1572015/
- 12 European Directorate for the Quality of Medicines & HealthCare (EDQM). Raw materials for the production of cell-based and gene therapy products, chapter 5.2.12 [draft prepared for consultation]. In: European Pharmacopoeia (9th Edi.), Druckeri C.H. Beck, Nordlingen, Germany (2016).
- 13 US Pharmacopeia. Ancillary aterials for cell, gene and tissue-engineered products. Chapter 1043 (2016). www.pharmacopeia.cn/v29240/usp29nf24s0_c1043.html
- 14 Department of Health and Social Care. The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO). Donation of starting material for cell-based advanced therapies: a SaBTO review (2014). www.gov.uk/government/publications/donation-of-starting-material-for-advanced-cell-based-therapies
- 15 Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications. Regen. Med. 10(2 s), 1–44 (2015). •• A consensus from leading stem cell researchers, biobanks and regulatory representatives from 24 countries on the key issues to be addressed for delivery of ethically and scientifically robust human pluripotent stem cells (hPSC) lines for human use.
- 16 . Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 132(4), 661–680 (2008).
- 17 Differentiated human stem cells resemble fetal, not adult, β cells. Proc. Natl Acad. Sci. USA 111(8), 3038–3043 (2014).
- 18 . Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes. J. Mol. Cell Cardiol. 67, 12–25 (2014).
- 19 Assessing the safety of human pluripotent stem cells (PSCs) and their derivatives for clinical applications. Stem Cell Reports 9(1), 1–4 (2017). •• An expert consensus report on the current state of knowledge regarding the impact of genetic changes in hPSC cultures. It proposed the establishment of an international database of genetic changes observed in these cultures.
- 20 Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat. Biotechnol. 29(12), 1132–1144 (2011). • Discovery of a single nucleotide polymorphism mutation on Chr20 common to numerous hPSC lines. The association with an antiapoptotic gene suggested a role of this genetic change in stabilizing stem cell cultures.
- 21 Report of the International Stem Cell Banking Initiative Workshop activity: current hurdles and progress in seed-stock banking of human pluripotent stem cells. Stem Cells Transl. Med. 6 (11), 1956–1962 (2017).
- 22 Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl. Med. 4(4), 389–400 (2015).
- 23 Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies. NPJ Regen. Med. 2(1), 28 (2017).
- 24 Stability of human mesenchymal stem cells during in vitro culture: considerations for cell therapy. Cell Prolif. 46(1), 10–22 (2013).
- 25 The Medicines and Healthcare products Regulatory Agency (MHRA) Innovation Office www.gov.uk/government/groups/mhra-innovation-office
